TIDMVAL
RNS Number : 3219R
ValiRx PLC
14 June 2018
VALIRX PLC
("ValiRx", the "Company" or the "Group")
VAL401 UPDATE
London, UK., 14 June 2018: ValiRx Plc (AIM: VAL), the clinical
stage biotechnology company, is pleased to provide an update on the
VAL401 commercial development.
The VAL401 clinical trial and data collection is now complete
and the regulatory process is moving towards completion with the
Clinical Study Report on schedule for submission within the
regulatory timeframe of two years from trial approval (July 2018).
These current and future development updates now focus on the
commercial aspects of the completed science development.
Since the results were released from the VAL401 trial on 16
January 2018, the development has focussed on commercial areas. An
advisory board of UK Key Opinion Leaders was consulted, addressing
the significance of the results obtained and the positioning of
VAL401 in the UK and global market. Advanced conversations have
continued with a number of prospective partners with the aim of
achieving a partnership, to progress the project appropriately
towards eventual patient use. Further validation of the project is
demonstrated by the approval of a second patent in New Zealand -
further details re set out below.
Advisory board of UK Key Opinion Leaders ("Advisory Board")
An Advisory board consisting of members of the patient advocate,
hospital and consultant community, all with specialisms in oncology
and particularly in end-of-life care in cancer patients was
convened to discuss the results and impact of VAL401. The meeting
was organised and executed by the independent communications
company, Hayward Medical, who provided a report detailing the ideas
and enthusiasm the participants showed for the development of
VAL401 to date. In particular the need for a treatment that can be
used to alleviate symptoms even in end-stage patients was
highlighted and that the co-prescription of a drug to provide
supportive benefits in addition to anti-cancer benefits would be
valuable from the beginning of the patient journey, alongside
currently used approaches.
The participants' individual comments included that they would
be confident taking VAL401 immediately on cancer diagnosis,
alongside standard of care treatment; that every month of
additional life secured is priceless, particularly with maintained
quality, and in fact that, terminal patients often prefer to retain
their Quality of Life than to risk further disruptive
treatments.
2018 BIO International Convention
Dr Dilly attended the BIO International Convention in Boston
during the week of 4 June 2018. Recognised as the largest
partnering and exhibition event in the industry, BIO is an
opportunity to access global biotech and pharma companies.
Presenting the VAL401 project, Dr Dilly held meetings to progress
commercial conversations further with current and future partners,
as well as presenting the project to new audiences.
Notification of Acceptance re Second New Zealand patent
ValiSeek has received notification that a further
method-of-treatment patent has been allowed by the New Zealand
Patent Office covering the use of VAL401 in the treatment of
pancreatic adenocarcinoma.
Dr Suzy Dilly, CEO of ValiSeek, commented: "The external
validation from both the Advisory Board and wider industry, has
provided increased confidence that VAL401, the product, has a
valued and needed place in the market. These developments are a
valuable addition to our licensing package, clarifying the final
stages of clinical testing towards commercial use."
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
*** ENDS ***
For more information, please contact:
ValiRx plc Tel: +44 (0) 20 3008 4416
www.valirx.com
Dr Satu Vainikka, Chief Executive Tel: +44 (0) 20 3008 4416
Tarquin Edwards, Head of Communications. Tel: +44 (0) 7879 458
364
tarquin.edwards@valirx.com
Cairn Financial Advisers LLP (Nominated Tel: +44 (0) 20 7213 0880
Adviser)
Liam Murray / Jo Turner
Novum Securities Limited Tel: +44 (0) 20 7399 9400
Colin Rowbury
Notes for Editors
About ValiSeek
ValiSeek Limited ("ValiSeek") is a joint venture ("JV") company
between ValiRx Plc and Tangent Reprofiling Limited, part of the
SEEK Group. ValiSeek was formed to progress the drug VAL401 through
its remaining preclinical development and towards Phase II trials
for the treatment of lung cancer and other oncology
indications.
About ValiRx
ValiRx is a biotechnology oncology focused company specialising
in developing novel treatments for cancer and associated
biomarkers. It aims to make a significant contribution in
"precision" medicine and science, namely to engineer a breakthrough
into human health and well-being, through the early detection of
cancer and its therapeutic intervention.
The Company's business model focuses on out-licensing
therapeutic candidates early in the development process. By aiming
for early-stage value creation, the company reduces risk
considerably while increasing the potential for realising value.
The group is already in licensing discussions with major players in
the oncology field.
ValiRx's two classes of drugs in development, which each have
the potential for meeting hitherto unmet medical needs by existing
methods, have worldwide patent filings and agreed commercial
rights. They originate or derive from World class institutions,
such as Cancer Research UK and Imperial College.
Until recently, cancer treatments relied on non-specific agents,
such as chemotherapy. With the development of target-based agents,
primed to attack cancer cells only, less toxic and more effective
treatments are now possible. New drugs in this group-such as those
in ValiRx's pipeline-promise to greatly improve outcomes for cancer
patients.
The Company listed on the AIM Market of the London Stock
Exchange in October 2006 and trades under the ticker symbol:
VAL.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
UPDLLFVERFIVLIT
(END) Dow Jones Newswires
June 14, 2018 02:00 ET (06:00 GMT)
Valirx (LSE:VAL)
Historical Stock Chart
From May 2024 to Jun 2024
Valirx (LSE:VAL)
Historical Stock Chart
From Jun 2023 to Jun 2024